Is Voyager Therapeutics Inc (VYGR) overvalued? · rev $80.0M
Voyager Therapeutics Inc (VYGR) is a biotechnology company listed on NASDAQ.
This page asks whether Voyager Therapeutics Inc (VYGR) looks expensive on cached numbers — not a short thesis.
Latest reported VYGR revenue for 2024-12-31 was $80.0M. Net income was -$65.0M. Revenue was down 68.0% from 2023-12-31 to 2024-12-31. VYGR currently screens at market cap $225.4M.
VYGR currently screens at market cap $225.4M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next VYGR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the VYGR stock page for the full model, not this heading.
Not investment advice.